Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
Identifieur interne : 001613 ( PubMed/Corpus ); précédent : 001612; suivant : 001614Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
Auteurs : B A Faucheux ; N. Nillesse ; P. Damier ; G. Spik ; A. Mouatt-Prigent ; A. Pierce ; B. Leveugle ; N. Kubis ; J J Hauw ; Y. AgidSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1995.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antibody Specificity, Humans, Immunoblotting, Immunohistochemistry, Lactoferrin (metabolism), Microcirculation (chemistry), Microcirculation (cytology), Neuroglia (chemistry), Neuroglia (cytology), Neurons (chemistry), Neurons (cytology), Parkinson Disease, Receptors, Cell Surface (analysis), Receptors, Cell Surface (immunology), Substantia Nigra (blood supply), Substantia Nigra (chemistry), Substantia Nigra (cytology).
- MESH :
- chemical , analysis : Receptors, Cell Surface.
- chemical , immunology : Receptors, Cell Surface.
- chemical , metabolism : Lactoferrin.
- blood supply : Substantia Nigra.
- chemistry : Microcirculation, Neuroglia, Neurons, Substantia Nigra.
- cytology : Microcirculation, Neuroglia, Neurons, Substantia Nigra.
- Aged, Aged, 80 and over, Antibody Specificity, Humans, Immunoblotting, Immunohistochemistry, Parkinson Disease.
Abstract
The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.
PubMed: 7568181
Links to Exploration step
pubmed:7568181Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.</title><author><name sortKey="Faucheux, B A" sort="Faucheux, B A" uniqKey="Faucheux B" first="B A" last="Faucheux">B A Faucheux</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale, Unité 289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nillesse, N" sort="Nillesse, N" uniqKey="Nillesse N" first="N" last="Nillesse">N. Nillesse</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Spik, G" sort="Spik, G" uniqKey="Spik G" first="G" last="Spik">G. Spik</name></author><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name></author><author><name sortKey="Pierce, A" sort="Pierce, A" uniqKey="Pierce A" first="A" last="Pierce">A. Pierce</name></author><author><name sortKey="Leveugle, B" sort="Leveugle, B" uniqKey="Leveugle B" first="B" last="Leveugle">B. Leveugle</name></author><author><name sortKey="Kubis, N" sort="Kubis, N" uniqKey="Kubis N" first="N" last="Kubis">N. Kubis</name></author><author><name sortKey="Hauw, J J" sort="Hauw, J J" uniqKey="Hauw J" first="J J" last="Hauw">J J Hauw</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:7568181</idno><idno type="pmid">7568181</idno><idno type="wicri:Area/PubMed/Corpus">001613</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001613</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.</title><author><name sortKey="Faucheux, B A" sort="Faucheux, B A" uniqKey="Faucheux B" first="B A" last="Faucheux">B A Faucheux</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale, Unité 289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Nillesse, N" sort="Nillesse, N" uniqKey="Nillesse N" first="N" last="Nillesse">N. Nillesse</name></author><author><name sortKey="Damier, P" sort="Damier, P" uniqKey="Damier P" first="P" last="Damier">P. Damier</name></author><author><name sortKey="Spik, G" sort="Spik, G" uniqKey="Spik G" first="G" last="Spik">G. Spik</name></author><author><name sortKey="Mouatt Prigent, A" sort="Mouatt Prigent, A" uniqKey="Mouatt Prigent A" first="A" last="Mouatt-Prigent">A. Mouatt-Prigent</name></author><author><name sortKey="Pierce, A" sort="Pierce, A" uniqKey="Pierce A" first="A" last="Pierce">A. Pierce</name></author><author><name sortKey="Leveugle, B" sort="Leveugle, B" uniqKey="Leveugle B" first="B" last="Leveugle">B. Leveugle</name></author><author><name sortKey="Kubis, N" sort="Kubis, N" uniqKey="Kubis N" first="N" last="Kubis">N. Kubis</name></author><author><name sortKey="Hauw, J J" sort="Hauw, J J" uniqKey="Hauw J" first="J J" last="Hauw">J J Hauw</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antibody Specificity</term><term>Humans</term><term>Immunoblotting</term><term>Immunohistochemistry</term><term>Lactoferrin (metabolism)</term><term>Microcirculation (chemistry)</term><term>Microcirculation (cytology)</term><term>Neuroglia (chemistry)</term><term>Neuroglia (cytology)</term><term>Neurons (chemistry)</term><term>Neurons (cytology)</term><term>Parkinson Disease</term><term>Receptors, Cell Surface (analysis)</term><term>Receptors, Cell Surface (immunology)</term><term>Substantia Nigra (blood supply)</term><term>Substantia Nigra (chemistry)</term><term>Substantia Nigra (cytology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Receptors, Cell Surface</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Receptors, Cell Surface</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Lactoferrin</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Microcirculation</term><term>Neuroglia</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Microcirculation</term><term>Neuroglia</term><term>Neurons</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antibody Specificity</term><term>Humans</term><term>Immunoblotting</term><term>Immunohistochemistry</term><term>Parkinson Disease</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7568181</PMID><DateCreated><Year>1995</Year><Month>11</Month><Day>14</Day></DateCreated><DateCompleted><Year>1995</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>92</Volume><Issue>21</Issue><PubDate><Year>1995</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.</ArticleTitle><Pagination><MedlinePgn>9603-7</MedlinePgn></Pagination><Abstract><AbstractText>The degeneration of nigral dopaminergic neurons in Parkinson disease is believed to be associated with oxidative stress. Since iron levels are increased in the substantia nigra of parkinsonian patients and this metal catalyzes the formation of free radicals, it may be involved in the mechanisms of nerve cell death. The cause of nigral iron increase is not understood. Iron acquisition by neurons may occur from iron-transferrin complexes with a direct interaction with specific membrane receptors, but recent results have shown a low density of transferrin receptors in the substantia nigra. To investigate whether neuronal death in Parkinson disease may be associated with changes in a pathway supplementary to that of transferrin, lactoferrin (lactotransferrin) receptor expression was studied in the mesencephalon. In this report we present evidence from immunohistochemical staining of postmortem human brain tissue that lactoferrin receptors are localized on neurons (perikarya, dendrites, axons), cerebral microvasculature, and, in some cases, glial cells. In parkinsonian patients, lactoferrin receptor immunoreactivity on neurons and microvessels was increased and more pronounced in those regions of the mesencephalon where the loss of dopaminergic neurons is severe. Moreover, in the substantia nigra, the intensity of immunoreactivity on neurons and microvessels was higher for patients with higher nigral dopaminergic loss. These data suggest that lactoferrin receptors on vulnerable neurons may increase intraneuronal iron levels and contribute to the degeneration of nigral dopaminergic neurons in Parkinson disease.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Faucheux</LastName><ForeName>B A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Institut National de la Santé et de la Recherche Médicale, Unité 289, Hôpital de la Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nillesse</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Spik</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mouatt-Prigent</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leveugle</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kubis</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hauw</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C038340">lactoferrin receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D007781">Lactoferrin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1992 Oct 2;592(1-2):8-16</RefSource><PMID Version="1">1450923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1992 Oct 16;593(2):343-6</RefSource><PMID Version="1">1450944</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 1990 Jan 16;29(2):535-41</RefSource><PMID Version="1">2154249</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1991 Feb;56(2):446-51</RefSource><PMID Version="1">1988548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1991 Mar;56(3):978-82</RefSource><PMID Version="1">1704426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Park Dis Dement Sect. 1990;2(4):327-40</RefSource><PMID Version="1">2078310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Aug;114 ( Pt 4):1953-75</RefSource><PMID Version="1">1832073</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 1991 Oct;114(1):73-81</RefSource><PMID Version="1">1915737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1991 Oct;114 ( Pt 5):2283-301</RefSource><PMID Version="1">1933245</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1992 Sep;59(3):1168-71</RefSource><PMID Version="1">1494904</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992;32 Suppl:S101-4</RefSource><PMID Version="1">1510366</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992;32 Suppl:S62-8</RefSource><PMID Version="1">1510382</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1992 Jul 10;585(1-2):87-93</RefSource><PMID Version="1">1511337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1992 Nov;59(5):1609-23</RefSource><PMID Version="1">1402908</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992 Dec;32(6):804-12</RefSource><PMID Version="1">1471873</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Neurol. 1993;60:148-64</RefSource><PMID Version="1">8420132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 1993 Jan 15;72(1):19-28</RefSource><PMID Version="1">8380757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 1992 Nov-Dec;12(6B):2047-51</RefSource><PMID Version="1">1338274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1993 Mar 26;606(2):341-5</RefSource><PMID Version="1">8098254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1993 Jun;60(6):2338-41</RefSource><PMID Version="1">8492137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1993 May;142(5):1574-85</RefSource><PMID Version="1">8494052</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Biochem. 1993 May 1;213(3):1205-11</RefSource><PMID Version="1">8389297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nutr Rev. 1993 Jun;51(6):157-70</RefSource><PMID Version="1">8371846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1994 Sep;63(3):793-807</RefSource><PMID Version="1">7519659</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol. 1994 Aug;267(2 Pt 1):G308-15</RefSource><PMID Version="1">8074229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1994 Sep 17;344(8925):796-8</RefSource><PMID Version="1">7916079</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1994 Jul 4;650(1):20-31</RefSource><PMID Version="1">7953673</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropathol Appl Neurobiol. 1994 Oct;20(5):468-72</RefSource><PMID Version="1">7845532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Suppl. 1994;43:123-32</RefSource><PMID Version="1">7884394</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cell Biol. 1994 Oct;65(1):164-71</RefSource><PMID Version="1">7889987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem J. 1995 Jun 1;308 ( Pt 2):391-7</RefSource><PMID Version="1">7772018</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1995 Sep 11;691(1-2):115-24</RefSource><PMID Version="1">8590043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 1960 Dec 18;45:413-21</RefSource><PMID Version="1">13772242</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1967 May;17(5):427-42</RefSource><PMID Version="1">6067254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 1972 Feb 29;257(2):314-23</RefSource><PMID Version="1">4336719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stroke. 1981 Jan-Feb;12(1):40-6</RefSource><PMID Version="1">6164135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1984 Mar;11(3):595-603</RefSource><PMID Version="1">6717804</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1984 Nov 8-14;312(5990):162-3</RefSource><PMID Version="1">6095085</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Physiol Rev. 1987 Apr;67(2):520-82</RefSource><PMID Version="1">3550839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1987 Jul;70(1):264-70</RefSource><PMID Version="1">3036277</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1988 Jul 28;334(6180):345-8</RefSource><PMID Version="1">2899295</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 1988 Jul;41(1):52-7</RefSource><PMID Version="1">3402586</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Biochem. 1989 Feb 1;179(2):481-7</RefSource><PMID Version="1">2537213</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007781" MajorTopicYN="N">Lactoferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC40850</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7568181</ArticleId><ArticleId IdType="pmc">PMC40850</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001613 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001613 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7568181
|texte= Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7568181" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |